Calidi Biotherapeutics (CLDI)
NYSE MKT:CLDI
US Market
Holding CLDI?
Track your performance easily

Calidi Biotherapeutics (CLDI) Income Statement

165 Followers

Calidi Biotherapeutics Income Statement

Last quarter (Q2 2024), Calidi Biotherapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Calidi Biotherapeutics's net income was $-7.44M. See Calidi Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21
Total Revenue
--$ 45.00K-
Cost of Revenue
--$ 14.00K-
Gross Profit
--$ 31.00K-
Operating Expense
$ 24.49M$ 28.99M$ 23.17M$ 1.78M
Operating Income
$ -37.99M$ -28.99M$ -23.13M$ -1.78M
Net Non Operating Interest Income Expense
$ 4.41M$ 3.75M$ 158.00K$ 1.67K
Other Income Expense
$ -488.17K$ 656.00K$ -2.13M$ -5.66M
Pretax Income
$ -35.83M$ -29.20M$ -25.42M$ 3.39M
Tax Provision
$ -115.42K$ 16.00K$ 11.00K$ -373.15K
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
$ -38.15M$ -29.22M$ -25.43M$ 3.88M
Basic EPS
$ -1.16$ -1.73$ 0.23$ 0.03
Diluted EPS
$ -1.16$ -1.73$ 0.23$ 0.03
Basic Average Shares
$ 88.67M$ 16.89M$ 23.42M$ 14.64M
Diluted Average Shares
$ 88.67M$ 16.89M$ 23.42M$ 14.64M
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
$ 24.49M$ 26.11M$ 23.17M$ 1.78M
Net Income From Continuing And Discontinued Operation
$ -35.72M$ -29.22M$ -25.43M$ 3.39M
Normalized Income
$ -28.27M$ -23.07M-$ 3.01M
Interest Expense
----
EBIT
$ -22.33M$ -28.13M$ -25.26M$ 3.39M
EBITDA
$ -21.18M$ -26.88M$ -25.00M$ 3.39M
Currency in USD

Calidi Biotherapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis